Clinical Trials · NCT07139548
A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Enrollment
- 600
- Start date
- Aug 2025
- Locations
- 1 site, China
- Primary endpoint
- Change From Baseline in Hemoglobin A1c (HbA1c) (6 mg and 9 mg)